Refine by
Arterial Disease Articles & Analysis: Older
103 news found
The publication presents results obtained from flow simulations in the coronary arteries of 25 patients with different degrees of stenoses and areas of occurrence. ...
About atrial fibrillation (AF) and chronic kidney disease (CKD) AF is the most common sustained cardiac rhythm disorder. ...
ByBayer AG
This progress highlights the potential for gene therapy to go beyond rare diseases and to address larger patient populations with significant unmet needs, such as chronic cardiovascular diseases. ...
Alucent is currently developing its Natural Vascular Scaffolding (Alucent NVS) Vessel Restoration System with Photoactivated Linking for the treatment of peripheral artery disease (PAD) of the lower extremities. The company announced today it will also seek to adapt the technology for another use, the maturation and preservation of arteriovenous fistula (AVF) for ...
The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of ...
This prospective, multicenter registry will enroll up to 400 female patients with symptomatic ischemic heart disease in up to 50 investigational centers in the United States and Europe and will include a 3-year follow-up. ...
” REVA’s MOTIV device represents a unique breakthrough technology for the treatment of patients suffering from below-the-knee peripheral vascular disease. MOTIV is a drug-eluting bioresorbable peripheral vascular scaffold made from REVA’s proprietary Tyrocore polymer that is designed to dissolve over time, leaving the artery free of a permanent ...
CardioWise, Inc., is pleased to announce that Perry Johnson Registrars, Incorporated has audited the CardioWise Quality Management System (QMS) and determined CardioWise is in conformance with ISO 13485:2016. Perry Johnson Registrars Certificate C2022-02910 was issued July 16, 2022, and represents the first step in the process of obtaining a CE mark and Medical Device Registration for the ...
ArterioSorb is an innovative medical implant product currently being developed by Arterius, a UK medical device micro/SME, to treat coronary artery disease (CAD). CAD is the leading cause of death both in the UK and worldwide, responsible for more than 73,000 deaths in the UK each year. ArterioSorb™ is a next-generation bioresorbable cardiovascular scaffold ...
With its ready-to-use models and assays for cardiac diseases, customers can accurately analyze the relationship between diseases and mitochondria. Mitochondrial DNA (mtDNA) plays an important role in the pathogenesis of the cardiovascular disease (CVD), especially in heart failure and ischemic heart disease. ...
XC001 is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow. By restoring blood flow, chest pain associated with refractory angina may decrease, potentially improving patients’ quality of life by enabling them to engage in daily physical activities that would otherwise cause pain. ...
The Ministry of Health, Labor and Welfare in Japan has approved the use of the oral Factor Xa inhibitor rivaroxaban (Xarelto™) (2.5 mg twice daily, used in combination with aspirin 81-100 mg once daily) to treat patients with peripheral artery disease (PAD) after revascularization. The approval is based on data from the Phase III VOYAGER PAD trial. ...
ByBayer AG
The Company’s products include MOTIV bioresorbable scaffolds for the treatment of peripheral artery disease, Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease, and TyroSphere embolic beads. ...
As Cardionovum® we are fully convinced that our LEGFLOW® DCB, with its unique coating Safepax® technology, will deliver to the patients the best results for the treatment of the peripheral arteries diseases.” ...
Cardiac CT combined with SQuEEZ analysis software can provide clinicians with a normalized measurement to determine the answer to the first and most important clinical question a cardiac surgeon needs to know for patients with Cardiovascular Disease (CVD) symptoms— “Is the contractile function normal or not ...
The Company’s products include MOTIV bioresorbable scaffolds for the treatment of peripheral artery disease, Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease, and TyroSphere embolic beads. ...
The Shockwave M5 and S4 IVL Catheters, which are used for the treatment of peripheral arterial calcification lesions, are approved in the United States, the European Union, and other select international jurisdictions and have been used to help treat more than 50,000 patients globally who suffer from peripheral arterial disease. The Shockwave C2 ...
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today new data confirming excellent one-year outcomes with coronary IVL in both women and men. The one-year results from the Disrupt CAD clinical program were presented at the 2022 Scientific Sessions of the Society for ...
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with IVL led to excellent long-term outcomes out to two years with preservation of future treatment options compared to percutaneous ...
Eleven SAEs were related to the underlying disease process or other causes. The other six SAEs which occurred in four subjects were judged to be related to the administration procedure, with none of those being unexpected nor resulting in patient death. ...